InCarda Therapeutics Welcomes Dr. Myles Greenberg as CEO
InCarda Therapeutics, a clinical-stage biopharmaceutical firm dedicated to developing cutting-edge treatments for cardiac arrhythmias, has appointed Dr. Myles Greenberg, MD, MBA, as its new Chief Executive Officer. Dr. Greenberg is set to lead the company as they work on their flagship product, an orally inhaled therapeutic designed for the swift conversion of atrial fibrillation (AF) to normal sinus rhythm.
Advancing Innovative Cardiac Treatments
The company's lead product harnesses a unique formulation of flecainide, an antiarrhythmic medication approved in the United States for over three decades. Traditionally used in oral form, flecainide has been pivotal in lowering the chances of recurrent and symptomatic paroxysmal atrial fibrillation (PAF) among individuals without pre-existing heart disease. By innovating the delivery method through inhalation, InCarda aims to expedite the restoration of normal heart rhythm, significantly improving patient outcomes.
Addressing the Atrial Fibrillation Challenge
AF is a prevalent and potentially severe condition impacting approximately 10 million individuals in the U.S. The symptoms can significantly impair one’s quality of life, and if left untreated, the risks escalate to strokes, heart failure, and potentially fatal outcomes. Moreover, AF tends to progress, with over 50% of PAF patients eventually developing persistent atrial fibrillation. This condition places a staggering economic burden on the healthcare system, estimated to reach as high as $26 billion.
Empowering Patients with Home-Based Treatment
Dr. Greenberg emphasized the company's commitment to empowering patients suffering from PAF. He stated, “Our mission at InCarda is to help patients manage their heart rhythm problems at home, providing them with the tools to take charge of their health and wellbeing. By achieving our goals, we can enhance their quality of life and minimize unnecessary hospital admissions and complications associated with AF.”
Dr. Greenberg’s Expertise
With nearly 25 years of experience in the life sciences sector, Dr. Greenberg brings a wealth of knowledge to InCarda Therapeutics. He has held key leadership roles as CEO, venture investor, and board member across various companies focused on innovative medical devices, biopharmaceuticals, and healthcare technology. Before transitioning into the biopharmaceutical sector, Dr. Greenberg practiced as an emergency physician at a prestigious Boston medical facility and served as an administrator in its emergency department.
Transitioning Leadership at InCarda
Dr. Greenberg takes the reins from interim CEO and cofounder Carlos Schuler, PhD, who moves into the role of Chief Technology Officer. Dan Welch, executive chairman of InCarda Therapeutics, expressed full confidence in Dr. Greenberg’s vision: “Myles possesses an intrinsic understanding of the obstacles in effectively managing cardiac arrhythmias such as paroxysmal atrial fibrillation. His leadership is expected to steer InCarda forward, addressing these challenges and enhancing care standards for patients and healthcare providers alike.”
The Future of Cardiac Care
The innovation behind InCarda’s product development symbolizes hope in the realm of cardiac care. The new leadership under Dr. Greenberg could position the company as a front-runner in transforming how PAF is treated, aiming for solutions that prioritize patient comfort and rapid relief of symptoms.
About InCarda Therapeutics
InCarda Therapeutics is dedicated to pioneering novel therapies targeting cardiovascular conditions. Supported by well-respected institutional investors such as Deerfield Management and HealthCap, InCarda's development focus remains on the innovative, orally inhaled formulation of flecainide, aiming to provide rapid relief for patients experiencing recent-onset paroxysmal atrial fibrillation. To learn more about InCarda Therapeutics and their developments, please visit incardatherapeutics.com.
Frequently Asked Questions
What is InCarda Therapeutics known for?
InCarda Therapeutics is focused on developing novel therapies for cardiac arrhythmias, especially paroxysmal atrial fibrillation.
Who is Dr. Myles Greenberg?
Dr. Myles Greenberg is the newly appointed CEO of InCarda Therapeutics, bringing extensive leadership experience in the life-sciences sector.
What is the significance of flecainide?
Flecainide is an established antiarrhythmic medication used to treat and manage atrial fibrillation, which InCarda is innovating for inhalation delivery.
How does InCarda aim to improve patient care?
InCarda aims to empower patients to manage their heart rhythm conditions at home, thereby reducing hospitalizations and complications.
What challenges does atrial fibrillation present?
Atrial fibrillation can lead to serious health complications, including strokes and heart failure if not properly managed.
